@ARTICLE{
author={Kao SCH,Reck M,Liu SV,Dziadziuszko R,Hochmair MJ,Huemer F,Gilberto de Castro J,Bernabe Caro R,Kim SH,Kowalski DM,Andric Zoran G,Oancea M,Kaul M,Li H,Danner B,Lee MC,Nabet BY,Sugawara S},
year={2024},
title={Whole exome sequencing (WES) analyses from IMpower133 and 6-year (y) overall survival (OS) from IMbrella A in patients (pts) with extensive-stage small cell lung cancer (ESSCLC) treated with atezolizumab (atezo)},
journal={ANNALS OF ONCOLOGY},
volume={35},
number={},
pages={S1638-S1638},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Reck M,...,Andric Zoran G,...,(broj koautora 19)},
year={2022},
title={Avelumab vs Chemotherapy for First-line Treatment of Advanced PD-L1+NSCLC: Primary Analysis from JAVELIN Lung 100},
journal={JOURNAL OF THORACIC ONCOLOGY},
volume={17},
number={9},
pages={S39-S39},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Smit E,Reck M,Krzakowski M,Gridelli C,Curescu S,Berzinec Peter,Barata F,McDermott R,Jovanovic D,Magyarlo P},
year={2007},
title={Erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): interim results from the European subpopulation of the open-label TRUST study},
journal={EJC SUPPLEMENTS},
volume={5},
number={4},
pages={359-359},
document_type={Meeting Abstract},
}